Atai Life Sciences N.V. (ATAI) NASDAQ

4.58

+0.005(+0.11%)

Updated at September 08 03:03PM

Currency In USD

Atai Life Sciences N.V.

Address

Krausenstrasse 9-10

Berlin, 10117

Germany

Phone

49 89 2153 9035

Sector

Healthcare

Industry

Biotechnology

Employees

54

First IPO Date

June 18, 2021

Key Executives

NameTitlePayYear Born
Dr. Srinivas G. Rao M.D., Ph.D.Co-Founder & Chief Executive Officer834,4601969
Mr. Christian AngermayerFounder & Chairman of the Supervisory Board73,1041978
Ms. Anne JohnsonChief Financial Officer574,8151969
Dr. Kevin Craig M.D.Chief Medical Officer01973
Mr. Ryan Barrett J.D.General Counsel & Corporate Secretary01981
Dr. Gerd G. Kochendoerfer Ph.D.Chief Operating Officer01968
Dr. Glenn Short Ph.D.Chief Scientific Officer01970

Description

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.